TORONTO, Ontario, May 14, 2026
Apotex Inc. announced the commercial launch of Apo-Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada. The launch marks a major development in the Canadian diabetes market, expanding access to more affordable semaglutide-based therapy for adults with type 2 diabetes mellitus. Initial inventory is already shipping to wholesalers, with the product expected to reach pharmacies nationwide within the coming weeks.
Apo-Semaglutide Injection™ is approved in both 2 mg and 4 mg prefilled pen formats, supporting dosing options equivalent to branded semaglutide products. The once-weekly injectable therapy is indicated for improving glycemic control in adults with type 2 diabetes when used alongside diet and exercise. According to Apotex Inc., the device and administration instructions closely mirror the branded product, helping patients and healthcare providers transition more easily to the generic alternative.
Apo-Semaglutide Expands Affordable Diabetes Treatment Access
The launch comes amid rapidly growing global demand for GLP-1 receptor agonists, which are widely used for diabetes management and increasingly associated with obesity treatment markets. By introducing a lower-cost semaglutide option, Apotex aims to improve accessibility for Canadian patients while supporting healthcare system cost savings.
The company stated that Apo-Semaglutide Injection™ underwent Health Canada’s standard regulatory review process for peptide medicines and was developed in partnership with Orbicular Pharmaceutical Technologies. The therapy is available in dosing configurations supporting 0.25 mg, 0.5 mg, and 1 mg administration, matching currently available branded dosage strengths.
Martin Arès, President of Apotex Canada, stated that the launch reflects the company’s commitment to delivering high-quality and affordable treatment options while strengthening long-term healthcare accessibility across Canada.
Advertisement
Generic GLP-1 Market Continues to Expand
The introduction of Apo-Semaglutide Injection™ highlights the growing competitive landscape surrounding semaglutide-based therapies, one of the fastest-growing pharmaceutical categories globally. Branded semaglutide products, including Ozempic, have experienced unprecedented demand due to their effectiveness in blood sugar control and weight management.
As one of the largest Canadian-based pharmaceutical companies, Apotex Inc. continues expanding its portfolio across generic medicines, biosimilars, and branded pharmaceutical products. The company believes the launch of Apo-Semaglutide Injection™ will help improve treatment availability while contributing to more sustainable healthcare spending.
Healthcare professionals are advised to review the full product monograph for complete prescribing information, including warnings, precautions, and adverse event monitoring requirements.
Source: Apotex press release
